Runx2 mRNA Expression in the Tissue, Serum, and Circulating Non-Hematopoietic Cells of Patients with Thyroid Cancer
Runx2 mRNA Expression in the Tissue, Serum, and Circulating Non-Hematopoietic Cells of Patients with Thyroid Cancer
复制标题
DOI：
10.1210/jc.2011-2624
复制
发表时间：
2012-07-01
影响因子：
5.8
通讯作者：
Valenti, Maria Teresa
中科院分区：
文献类型：
--
作者：
Carbonare, Luca Dalle;Frigo, Anna;Valenti, Maria Teresa
背景：Runx2是成骨分化的主要基因，在非骨性癌细胞中也有表达。微小钙化是甲状腺乳头状癌的特征，是诊断的有用发现。目的：研究成骨分化转录因子Runx2在正常和病理甲状腺组织、血清和循环非造血细胞中的表达。背景：本研究在意大利维罗纳“Azienda Ospedaliera unisitaria Integrata”内科内分泌室进行。结果：Runx2基因在甲状腺病变组织中的表达是正常组织的7.81倍(P<；0.05)。Runx2mRNA在PTC患者血清和循环中的非造血细胞中也有高表达(分别为5.91倍和3.82倍，P<0.001)。我们还观察到，有微钙化的患者血清中Runx2的表达水平显著高于无微钙化的患者(P<；0.05)。结论：这项研究可以为PTC的诊断和随访开辟新的研究视角，尽管还需要进一步的更大规模的队列研究来验证Runx2作为甲状腺癌生物标志物的有效性。(J临床内分泌Metab 97：E1249-E1256,2012)
Context: Runx2, a master gene of osteogenic differentiation, is also expressed in nonosseous cancer cells. Microcalcifications are characteristic of papillary thyroid carcinoma and represent a useful find for diagnosis. However, the molecular expression of osteogenic differentiation transcription factor Runx2 has been poorly investigated in this tumor.Objective: The aim of this study was to investigate Runx2 mRNA expression in normal and pathological thyroid tissue, serum, and circulating non-hematopoietic cells.Setting: The study was performed in the Endocrine Unit of Internal Medicine of "Azienda Ospedaliera Universitaria Integrata of Verona" (Verona, Italy).Patients: We enrolled 12 patients with a papillary thyroid carcinoma (PTC), who had undergone total thyroidectomy performed by the same surgeon. The results, obtained by real-time RT-PCR, were compared with biological samples obtained from 13 sex-and age-matched normal donors.Results: Our data demonstrated that Runx2 mRNA is overexpressed (7.81-fold expression) in pathological thyroid tissue than in normal tissue (P < 0.05). Runx2 mRNA overexpression was also observed in serum and circulating non-hematopoietic cells of PTC patients with respect to normal donors (5.91-fold expression, P < 0.001; 3.82-fold expression, P < 0.05, respectively). We also observed that patients with microcalcifications expressed significantly higher levels of Runx2 mRNA in serum with respect to patients without microcalcifications (P < 0.05).Conclusion: This study can open up new research perspectives in the diagnosis and follow-up of PTC, even if further and larger cohort studies will be necessary to validate the Runx2 expression as biomarkers in thyroid cancer. (J Clin Endocrinol Metab 97: E1249-E1256, 2012)